1.	Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Phase: Phase IV Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0208, NCT00679536
2.	Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
3.	Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Phase: Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0307, NCT00619879
4.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
5.	Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase: Phase III Type: Treatment Status: Active Age: 3 to 70 Sponsor: Other Protocol IDs: 2011-0628, NCT01471444
6.	Chemotherapy Followed by Allogeneic Stem Cell Transplantation in Treating Children With Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 4 to 21 Sponsor: NCI Protocol IDs: NCI-01-C-0125F, NCT00020592
7.	Stem Cell Transplant for Hematologic Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
8.	Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers Phase: Phase II, Phase I Type: Treatment Status: Active Age: 12 to 60 Sponsor: Pharmaceutical / Industry Protocol IDs: CB001, UMN-2003LS055, UMN-MT2003-20, VIACELL-CB001-03, UMN-0310M3141, NCT00089596
9.	Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
10.	Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 2005-0508, NCT00402558
11.	Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 55 Sponsor: NCI, Other Protocol IDs: 06-125, MSKCC-06125, NCT00423514
12.	Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
13.	Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed By Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 60 Sponsor: Other Protocol IDs: MT2000-09, 0001M34441, UMN-MT2000-09, UMN-2007BMT031, NCT00630253
14.	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776
15.	Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 74 Sponsor: NCI Protocol IDs: 080051, 08-C-0051, NCT00923910
16.	5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 2009-0467, NCT01038635
17.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
18.	Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell Phase: Phase II, Phase I Type: Treatment Status: Active Age: 13 to 60 Sponsor: NCI, Other Protocol IDs: BMT236, SU-09142011-8407, NCT01660607
19.	Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Phase: Phase II Type: Treatment Status: Active Age: 8 to 80 Sponsor: NHLBI Protocol IDs: 990050, 99-H-0050, NHLBI-99-H-0050, NCT00003838
20.	Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 65 and under Sponsor: NCI Protocol IDs: CPMC-IRB-AAAA5571, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
21.	Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: PSCI-2003-232, NCT00084695
22.	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer Phase: Phase II Type: Supportive care, Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1898.00, NCI-2010-00267, P01HL036444, P01CA078902, FHCRC-1898.00, 5788, NCT00089011
23.	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase: Phase II Type: Treatment Status: Active Age: 16 to 50 Sponsor: NCI, Other Protocol IDs: 1809.00, NCI-2010-00234, FHCRC-1809.00, 5602, NCT00119366
24.	HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Phase: Phase II Type: Treatment Status: Active Age: Under 24 months Sponsor: Other Protocol IDs: INF-T2, NCT00145626
25.	Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer Phase: Phase II Type: Treatment Status: Active Age: 45 and under Sponsor: Other Protocol IDs: 2005LS043, UMN-MT2005-10, UMN-0507M71475, UMN-2005LS043, UMN-BMT-MT2005-10, NCT00309842